NH.NSE

Narayana Hrudayalaya Ltd

… hospital chains and the broader healthcare provider sector. Central to Bessemer … cumulative PE investment in offline healthcare providers at $10.6 billion … such as Apollo Hospitals, Max Healthcare , Fortis Healthcare , Narayana Hrudayalaya, and others …

Narayana Hrudayalaya Ltd. ( ($IN:NH) ) just unveiled an update. Narayana Hrudayalaya Ltd. has incorporated a new wholly owned subsidiary, Narayana ...

Narayana Hrudayalaya Ltd. ( ($IN:NH) ) just unveiled an update. Narayana Hrudayalaya Ltd. has incorporated a new wholly owned subsidiary, Narayana ...

In this briefing: ORMP: Advancing Clinical Activities RVPH: Brilaroxazine Poster Presentations WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Narayana Hrudayalaya: A Quarter of Record Performance and Strategic Expansion UltraGreen.ai IPO: High Growth and High Margins, Market Leader 1. ORMP: Advancing Clinical Activities ORMP is leveraging its strong balance sheet to invest in early stage companies, primarily focusing on the medical & biopharma space. ORMP has substantial liquidity as it both advances its oral drug delivery platform and pursues strategic opportunities, including strategic investments. The company received ~$27m on its Scilex investment in 3Q25, with the principal on the Scilex investment now fully repaid. 2. RVPH: Brilaroxazine Poster Presentations Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address multiple related mental disorders, rare diseases & other categories of un met need.

In this briefing: ORMP: Advancing Clinical Activities RVPH: Brilaroxazine Poster Presentations WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Narayana Hrudayalaya: A Quarter of Record Performance and Strategic Expansion UltraGreen.ai IPO: High Growth and High Margins, Market Leader 1. ORMP: Advancing Clinical Activities ORMP is leveraging its strong balance sheet to invest in early stage companies, primarily focusing on the medical & biopharma space. ORMP has substantial liquidity as it both advances its oral drug delivery platform and pursues strategic opportunities, including strategic investments. The company received ~$27m on its Scilex investment in 3Q25, with the principal on the Scilex investment now fully repaid. 2. RVPH: Brilaroxazine Poster Presentations Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address multiple related mental disorders, rare diseases & other categories of un met need.

In this briefing: RVPH: Brilaroxazine Poster Presentations WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Narayana Hrudayalaya: A Quarter of Record Performance and Strategic Expansion UltraGreen.ai IPO: High Growth and High Margins, Market Leader Monash IVF (MVF AU) Rejects Soul Patts/Genesis' Offer 1. RVPH: Brilaroxazine Poster Presentations Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address multiple related mental disorders, rare diseases & other categories of un met need. Reviva's lead indication in schizophrenia with brilaroxazine completed its Phase III RECOVER trial & may pursue future studies. 2. WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Key takeaways from 3Q25 earnings release. Lu highlighted Ainos’ strong revenue momentum, up more than 4x Y/Y, driven almost entirely by the deployment of AI Nose in senior care programs.

In this briefing: RVPH: Brilaroxazine Poster Presentations WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Narayana Hrudayalaya: A Quarter of Record Performance and Strategic Expansion UltraGreen.ai IPO: High Growth and High Margins, Market Leader Monash IVF (MVF AU) Rejects Soul Patts/Genesis' Offer 1. RVPH: Brilaroxazine Poster Presentations Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address multiple related mental disorders, rare diseases & other categories of un met need. Reviva's lead indication in schizophrenia with brilaroxazine completed its Phase III RECOVER trial & may pursue future studies. 2. WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Key takeaways from 3Q25 earnings release. Lu highlighted Ainos’ strong revenue momentum, up more than 4x Y/Y, driven almost entirely by the deployment of AI Nose in senior care programs.

In this briefing: WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Narayana Hrudayalaya: A Quarter of Record Performance and Strategic Expansion UltraGreen.ai IPO: High Growth and High Margins, Market Leader Monash IVF (MVF AU) Rejects Soul Patts/Genesis' Offer Madrigal Pharma: Inside the MAESTRO-NASH Breakthrough- How Weight Loss Supercharges Antifibrotic Effects! 1. WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Key takeaways from 3Q25 earnings release. Lu highlighted Ainos’ strong revenue momentum, up more than 4x Y/Y, driven almost entirely by the deployment of AI Nose in senior care programs. Lu noted that the reported revenue has yet to include any of the $2.1-million, three-year AI Nose subscription order from a semiconductor customer, signaling additional upside in the SmellTech platform’s revenue, the turnaround in gross margin to 82% YTD from negative last year, and Ainos’ cost management with cash operating expenses reduced by 15% YTD versus the previous year.

In this briefing: WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Narayana Hrudayalaya: A Quarter of Record Performance and Strategic Expansion UltraGreen.ai IPO: High Growth and High Margins, Market Leader Monash IVF (MVF AU) Rejects Soul Patts/Genesis' Offer Madrigal Pharma: Inside the MAESTRO-NASH Breakthrough- How Weight Loss Supercharges Antifibrotic Effects! 1. WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Key takeaways from 3Q25 earnings release. Lu highlighted Ainos’ strong revenue momentum, up more than 4x Y/Y, driven almost entirely by the deployment of AI Nose in senior care programs. Lu noted that the reported revenue has yet to include any of the $2.1-million, three-year AI Nose subscription order from a semiconductor customer, signaling additional upside in the SmellTech platform’s revenue, the turnaround in gross margin to 82% YTD from negative last year, and Ainos’ cost management with cash operating expenses reduced by 15% YTD versus the previous year.